Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata

Brett King(Yale University), James V. Cassella(Trevi Therapeutics (United States)), Emma Guttman‐Yassky(Rockefeller University), Amy McMichael(Wake Forest University), Maria Colavincenzo(Northwestern University), Colleen Hamilton(Concert Pharmaceuticals (United States)), Suzanne Bruce(Houston Institute for Clinical Research), Paradi Mirmirani(Kaiser Permanente Vallejo Medical Center), Virginia Braman(Concert Pharmaceuticals (United States)), Steve Kempers(Minnesota Oncology), Janet L. Roberts(Oregon Dermatology & Research Center), Natasha Atanaskova Mesinkovska(University of California, Irvine)
Journal of the American Academy of Dermatology
March 29, 2022
10.1016/j.jaad.2022.03.045
Cited by 80

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
|The Lancet|2021|538
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|505
Non-lesional Atopic Dermatitis Skin Is Characterized by Broad Terminal Differentiation Defects and Variable Immune Abnormalities
|Journal of Allergy and Clinical Immunology|2011|457